# GalaxyBiomedical Investment

GalaxyBiomedical Investment is a Corporate Investor based in Beihai, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Beihai, China
- **Region:** Asia
- **Address:** Beihai, Guangxi, China
- **Founded:** 1993
- **Assets under management:** Undisclosed
- **Website:** www.g-biomed.com

## Regulatory record

- **Reports private funds:** No

## About

GalaxyBiomedical Investment was established in 1993 in Beihai, China, as a subsidiary of YH Group. Chairman Keyang Liu leads the firm, with co-founder Huang Jian having previously served as Chairman and Legal Representative. The firm's corporate structure ties its fortunes to the operating performance of its core biomedical holdings while leaving room for opportunistic diversification into industrial and real-asset categories. Portfolio companies include Nanjing Galaxy Biotechnology and Suzhou Galaxy Biomedical, which anchor a biopharma vertical focused on China's domestic market. Beyond biomedicine, the firm holds interests in distribution equipment and electronic components. A notable non-healthcare asset is the Galaxy Software Technology Park, a commercial real estate project on Xizang Road in Beihai. The firm draws on tight operational relationships with Beijing Teamsun Technology — linked through shared directorships — and with the China Venture Capital Research Institute, where executives serve on the East China Representative Office. Through subsidiary Liuzhou Special Transformer, GalaxyBiomedical holds a director-unit seat within the Transformer Branch of the China Electricity Industry Association, signaling a meaningful industrial manufacturing tilt. The firm's geographic footprint is concentrated in China's southern corridor, with headquarters in Beihai, operating entities in Nanjing and Suzhou, and a manufacturing presence in Liuzhou. No publicly disclosed AUM or deployment figures exist, which is characteristic of a holding company that measures itself by subsidiary revenue rather than third-party capital. The firm's structural identity is its operating-company DNA: it is not a pure financial allocator but a parent with direct control over subsidiaries that generate cash flows for reinvestment. This creates a permanent-capital base and a decision-making timeline that ignores fund cycles. Succession appears to rest with Keyang Liu, who holds both the Chairmanship and Board Secretary role, concentrating governance in a single executive.

## Sectors

- Biotech & Pharma
- Industrial Tech
- Real Estate
- Technology Services
- Electronics

## People

- Keyang Liu — Chairman and Secretary of the Board
- Huang Jian — Former Chairman and Legal Representative

## Questions

### Is GalaxyBiomedical a pure-play biomedical investor?

No. While the firm controls Nanjing Galaxy Biotechnology and Suzhou Galaxy Biomedical, its portfolio extends into distribution equipment, electronic components, and commercial real estate via the Galaxy Software Technology Park. It also has ties to the industrial transformer sector through subsidiary Liuzhou Special Transformer.

### What is GalaxyBiomedical's relationship with YH Group?

GalaxyBiomedical Investment was established as a subsidiary of YH Group in 1993. YH Group is the parent entity; GalaxyBiomedical operates as an investment and holding company underneath it. The exact ownership percentage or control mechanics between the two have not been publicly detailed.

### Which external partners does GalaxyBiomedical co-invest or collaborate with?

Close relationships exist with Beijing Teamsun Technology, linked through shared directorships, and with the China Venture Capital Research Institute, where GalaxyBiomedical executives sit on the East China Representative Office. The subsidiary Liuzhou Special Transformer holds a director-unit seat in the Transformer Branch of the China Electricity Industry Association. No fund-level co-investment partnerships have been disclosed.

## Related profiles

- [Galapagos Advisory](https://altss.com/profile/galapagos-advisory)
- [Gale & Phillipson](https://altss.com/profile/gale-phillipson)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/galaxybiomedical-investment

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology